Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer Using Infusional Gemcitabine: Immune Cell Infiltration Analysis and Updated Survival
Shouki Bazarbashi, Hadeel AlManea, Ali Aljubran, Ahmed Alzahrani, Ali Alqahtani, Fahad Almugbel, Muhammad Shahzad Rauf, Hazem Ghebeh · 2025
Read Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer Using Infusional Gemcitabine: Immune Cell Infiltration Analysis and Updated Survival by Shouki Bazarbashi, Hadeel AlManea, Ali Aljubran, Ahmed Alzahrani, Ali Alqahtani, Fahad Almugbel, Muhammad Shahzad Rauf, Hazem Ghebeh (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12730363.txt.
Description
Shouki Bazarbashi and co-authors update a phase II trial of chemoradiation before surgery for advanced rectal cancer. Standard care pairs radiation with one of two drugs. Their trial swapped in gemcitabine, a drug that also tunes immune response, given as a slow drip each week.
The 2025 update covers 40 adults whose tumors were large or had spread to nearby nodes, but not beyond. After treatment, 32 had surgery and 31 had the tumor fully removed. Median time without disease growth reached 70 months, with a median follow up of 87.4 months. The update also checks immune cells in tumor tissue before and after care, and weighs harms against past capecitabine results.
Catalog record
| CREATOR | Shouki Bazarbashi, Hadeel AlManea, Ali Aljubran, Ahmed Alzahrani, Ali Alqahtani, Fahad Almugbel, Muhammad Shahzad Rauf, Hazem Ghebeh |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 25 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |